fda tirzepatide obesity The has expanded the approval of Eli Lilly's medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity — the first medication approved for the The FDA approval of #zepbound

Clinical trials have shown that patients taking Semaglutide GLP-1 can lose an average of 10-15% of their body weight over a period of several months

It is not for injection alone

By addressing inflammation, pain processing, and metabolic health, they may offer benefits for some individuals further research is needed

Arunkanth Krishnakumar , Co-founder & CEO, Zeus Hygia Lifescience highlights, Looking ahead, the future of metabolic health lies in integrating pharmaceutical advancements with scientifically validated nutraceutical innovations

A limitation inherent to all long-term modeling studies in type 2 diabetes was the reliance on the projection of long-term outcomes from short-term clinical trial data